David Brennan

Latest Headlines

Latest Headlines

AstraZeneca shakeup leaves R&D chief on top of restructured MedImmune

The big shakeup under way at AstraZeneca under new CEO Pascal Soriot has hit home at MedImmune. Peter Greenleaf is out as president of the Gaithersburg, MD-based biotech division and Bahija Jallal, now a member of an R&D troika on AstraZeneca's executive group in the wake of Martin Mackay's ouster, is stepping up to the top spot.

Our top 5 biotech news stories on the web this year

In what has become a holiday tradition here at  FierceBiotech, we're offering readers a look back at our most popular stories of the year. Check it out >>

Profit plunge stokes M&A buzz as AstraZeneca chief vows to strike more deals

AstraZeneca has become one of the most active dealmakers in the industry in the months since David Brennan vacated the top post. But after a miserable sales performance in the last quarter--down 19%--the company made it clear that it needed to do a lot more, hinting that big things could be afoot.

New chief halts AZ buybacks to review strategy

AstraZeneca's ($AZN) new CEO wasted little time in making a big move. Pascal Soriot, who took the reins today, suspended the company's stock-buyback plan with $2.2 billion left to go on a $4.5 billion target for this year. The buybacks won't resume till after Soriot and the AstraZeneca board review their going-forward strategy--if then.

What will new CEO Soriot do now to fix AstraZeneca?

In many ways, Roche is everything that AstraZeneca is not but desperately wants to be--inventive, focused, with a reputation for success in biotech innovation. And that says a lot about the strategies that AstraZeneca will follow in the years ahead.

AstraZeneca faces fresh questions over MedImmune deal

About 5 years ago AstraZeneca's now ex-CEO David Brennan pulled the trigger on a $15.6 billion purchase of the biotech MedImmune, a move that would help define his tumultuous tenure as chief executive.

As sales slide AstraZeneca stays fixed on rapid-fire deal strategy

AstraZeneca has been under the gun recently for paying some hefty prices on a string of business deals for new products. But after reporting another dismal set of quarterly earnings--with sales plunging 21% on a combination of generic competition and European-style economizing--the pharma giant is signaling that the deal-making has just begun.

AZ's MedImmune axing 200 in California R&D restructuring

AstraZeneca's biotech arm, MedImmune, is doing its part in a corporate restructuring operation--axing 200 workers and relocating 100 others as it shutters a pair of facilities in California.

Ex-AstraZeneca chief forfeits up to £3.5M in exit pay

Ex-CEO David Brennan was expected to carry his moneybags out the door at AstraZeneca. Till now, just how much those bags would contain was open to speculation. Turns out that Brennan's retirement haul won't be as large as it could have been.

Pharma's Top 5 Golden Handshakes of the Last 5 Years

It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.